ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES
Dual antiplatelet therapy (acetylsalicylic acid and platelet P2Y12 receptor antagonist) is a standard component of treatment of any type of acute coronary syndrome, independently of perfusion and the chosen treatment strategy. Due to certain limitations of clopidogrel as the 2nd component of dual an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2018-07-01
|
| Series: | Klinicist |
| Subjects: | |
| Online Access: | https://klinitsist.abvpress.ru/Klin/article/view/335 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849336130513666048 |
|---|---|
| author | E. V. Konstantinova М. Yu. Gilyarov N. А. Shostak D. A. Anichkov |
| author_facet | E. V. Konstantinova М. Yu. Gilyarov N. А. Shostak D. A. Anichkov |
| author_sort | E. V. Konstantinova |
| collection | DOAJ |
| description | Dual antiplatelet therapy (acetylsalicylic acid and platelet P2Y12 receptor antagonist) is a standard component of treatment of any type of acute coronary syndrome, independently of perfusion and the chosen treatment strategy. Due to certain limitations of clopidogrel as the 2nd component of dual antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention, the possibility of using prasugrel or ticagrelor should be considered first. Their effectiveness is higher than clopidogrel’s, as was demonstrated in large clinical trials. As a result, prasugrel and ticagrelor were included in all major international and Russian guidelines on treatment of this category of patients with the same class and level of evidence. Currently, there’re no data from any finished large randomized clinical trials of sufficient statistical power directly comparing the effectiveness and safety of prasugrel and ticagrelor. Therefore, careful analysis of the accumulated data on the safety and effectiveness of each drug including meta-analyses and registries is necessary for providing the best care for every individual patient. |
| format | Article |
| id | doaj-art-6afb41262f76474286c4ba3055cdd42e |
| institution | Kabale University |
| issn | 1818-8338 |
| language | Russian |
| publishDate | 2018-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Klinicist |
| spelling | doaj-art-6afb41262f76474286c4ba3055cdd42e2025-08-20T03:45:04ZrusABV-pressKlinicist1818-83382018-07-01121101610.17650/1818-8338-2018-12-1-10-16287ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIESE. V. Konstantinova0М. Yu. Gilyarov1N. А. Shostak2D. A. Anichkov3N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation; N.I. Pirogov City Clinical Hospital No 1 named of Moscow Healthcare DepartmentN.I. Pirogov City Clinical Hospital No 1 named of Moscow Healthcare Department; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russian FederationN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russian FederationN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russian FederationDual antiplatelet therapy (acetylsalicylic acid and platelet P2Y12 receptor antagonist) is a standard component of treatment of any type of acute coronary syndrome, independently of perfusion and the chosen treatment strategy. Due to certain limitations of clopidogrel as the 2nd component of dual antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention, the possibility of using prasugrel or ticagrelor should be considered first. Their effectiveness is higher than clopidogrel’s, as was demonstrated in large clinical trials. As a result, prasugrel and ticagrelor were included in all major international and Russian guidelines on treatment of this category of patients with the same class and level of evidence. Currently, there’re no data from any finished large randomized clinical trials of sufficient statistical power directly comparing the effectiveness and safety of prasugrel and ticagrelor. Therefore, careful analysis of the accumulated data on the safety and effectiveness of each drug including meta-analyses and registries is necessary for providing the best care for every individual patient.https://klinitsist.abvpress.ru/Klin/article/view/335acute coronary syndromedual antiplatelet therapypercutaneous coronary interventionprasugrelticagrelorclopidogrelplatelet activationrandomized clinical studymeta-analysisreal clinical practice |
| spellingShingle | E. V. Konstantinova М. Yu. Gilyarov N. А. Shostak D. A. Anichkov ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES Klinicist acute coronary syndrome dual antiplatelet therapy percutaneous coronary intervention prasugrel ticagrelor clopidogrel platelet activation randomized clinical study meta-analysis real clinical practice |
| title | ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES |
| title_full | ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES |
| title_fullStr | ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES |
| title_full_unstemmed | ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES |
| title_short | ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES |
| title_sort | antiplatelet therapy of acute coronary syndrome current capab ilities |
| topic | acute coronary syndrome dual antiplatelet therapy percutaneous coronary intervention prasugrel ticagrelor clopidogrel platelet activation randomized clinical study meta-analysis real clinical practice |
| url | https://klinitsist.abvpress.ru/Klin/article/view/335 |
| work_keys_str_mv | AT evkonstantinova antiplatelettherapyofacutecoronarysyndromecurrentcapabilities AT myugilyarov antiplatelettherapyofacutecoronarysyndromecurrentcapabilities AT nashostak antiplatelettherapyofacutecoronarysyndromecurrentcapabilities AT daanichkov antiplatelettherapyofacutecoronarysyndromecurrentcapabilities |